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GLOSSARY OF KEY TERMS 
Terms Definition 
Medication errors Any preventable event that may cause or 
lead to inappropriate medication use or 
patient harm while the medication is in the 
control of the health care professional, 
patient, or consumer. Such events may be 
related to professional practice, health care 
products, procedures, and systems, including 
prescribing, order communication, product 
labeling, packaging, and nomenclature, 
compounding, dispensing, distribution, 
administration, education, monitoring, and 
use. 
 
Prescribing errors A clinically meaningful prescribing error 
occurs when, as a result of a prescribing 
decision or prescription writing process, there 
is an unintentional significant reduction in the 
probability of treatment being timely and 
effective and/or increase in the risk of harm 
when compared with generally accepted 
practice 
 
Prescribing errors without harm Categories (A-C) in the NCC MERP index 
Prescribing errors with potential 
to cause harm 
 
Category (D) in the NCC MERP index 
Prescribing errors with actual 
harm 
 
Categories (E-I) in the NCC MERP index 
Kappa An agreement measure beyond that agreement 
expected to occur by chance. 
 
Charlson’s Comorbidity Index 
Weight 
 
Is an index that predicts ten-year mortality for 
a patient who may have a range of comorbid 
conditions, such as heart disease, AIDS, 
or cancer (a total of 22 conditions). Each 
condition is assigned a score of 1, 2, 3, or 6, 
depending on the risk of dying associated 
with each one. Scores are summed to provide 
a total score to predict mortality. 
 
Incidence A measure of the probability of occurrence of 
a given medical condition in a population 
within a specified period of time. 
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PENILAIAN CABARAN KESELAMATAN UBAT  DAN SALAH 
PRESKRIPSI  DALAM KALANGAN PESAKIT DI SEBUAH HOSPITAL 
SWASTA DI ARAB SAUDI 
 
ABSTRAK 
 
Keselamatan ubat di hospital di Arab Saudi tidak diteroka sepenuhnya.  
Walaupun terdapat beberapa kajian yang dijalankan tentang salah preskripsi, namun 
tiada usaha sepakat tentang definisi salah preskripsi. Justeru, matlamat kajian ini 
adalah untuk meneroka perspektif profesional penjagaan kesihatan tentang 
keselamatan ubat, membangun satu definisi tentang salah preskripsi serta menilai 
insidens salah preskripsi di hospital di Riyadh, Arab Saudi. Kajian ini dijalankan 
dalam tiga fasa. Fasa pertama, merupakan perbincangan meja bulat dengan 
profesional penjagaan kesihatan. Fasa kedua, melibatkan proses Delphi dalam 
kalangan pengamal penjagaan kesihatan dengan para pakar dalam bidang 
keselamatan ubat dan pengurusan kualiti. Fasa ketiga atau terakhir, merupakan suatu 
kajian retrospektif yang melibatkan semakan carta perubatan dan arahan 
pengambilan ubat kepada pesakit pembedahan, pesakit perubatan dan pesakit di unit 
rawatan rapi (ICU), di hospital swasta, di Riyadh. Keterukan salah preskripsi yang 
dikenal pasti dinilai oleh pakar perunding (konsultan) melalui penggunaan algoritma 
NCC MERP (National Coordinating Council for Medication Error Reporting and 
Prevention). Dapatan kajian fasa pertama mengutarakan tiga tema utama: masalah 
keselamatan ubat, cabaran terhadap penambahbaikan amalan keselamatan ubat, dan 
cadangan  bagi penambahbaikan keselamatan ubat.  Dalam fasa kedua, sejumlah 35 
xvi 
 
orang pakar ikut serta dalam kajian ini, dan daripada jumlah tersebut, 31(88.5%)  
memberi respons dalam pusingan pertama. Dalam pusingan kedua, hanya 24 (68.5%)  
daripada mereka memberi respons. Mereka menerima definisi salah preskripsi. 
Berdasarkan jenis salah preskripsi, mereka bersetujua memasukkan 34 senario, 5 
senario, dan 3 senario bergantung pada situasi klinikal individu. Dalam kajian fasa 
ketiga, sejumlah 691 salah preskripsi dikenal pasti daripada fail 2,033 orang pesakit. 
Insidens salah preskripsi adalah 3.6 (95% CI, 3.3 - 3.9) per 100 preskripsi, 33.9 (95% 
CI, 31.5 - 36.6) per 100 kemasukan dan 76.5 (95% CI, 70.9 - 82.3) per 1000 hari 
pesakit.  Jenis salah preskripsi yang dikenal pasti paling biasa terjadi adalah salah 
dos (127; 18.4%) dengan 74 lebih-dos dan 53 kurang-dos. Antibiotik (230; 33.3%) 
adalah kelas drug paling biasa yang terlibat dengan salah preskripsi. Daripada salah 
preskripsi yang dikenal pasti, 20 (2.9%) adalah salah prekripsi yang benar, 
330(47.8%) salah prekripsi yang berpotensi dan 341(49.3%) salah preskripsi yang 
tidak memudaratkan. Terdapat beberapa cabaran  dalam konteks keselamatan ubat di 
Arab Saudi dan salah preskripsi adalah perkara biasa. Cadangan  atau saranan utama 
bagi penambahbaikan keselamatan ubat termasuk penggunaan teknologi, penilaian 
kemahiran pendidiikan yang berterusan, penyelidikan dan sokongan yang 
bersungguh-sungguh daripada, badan akreditasi hospital negara.  
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EVALUATION OF MEDICATION SAFETY CHALLENGES AND 
PRESCRIBING ERRORS AMONG HOSPITALIZED PATIENTS IN A 
SAUDI ARABIAN PRIVATE HOSPITAL 
 
 
                                           ABSTRACT 
 
Medication safety in Saudi hospitals has not been explored extensively. 
Although few studies have investigated prescribing errors, no attempts were made to 
develop a consensus definition of prescribing errors. Therefore, the aim of this study 
was to explore healthcare professionals’ perspectives about medication safety, 
develop a definition of prescribing errors and assess the incidence of prescribing 
errors in a private hospital in Riyadh, Saudi Arabia. The study was conducted in 
three phases. Phase one was an exploratory round-table discussion with healthcare 
professionals’. The second phase involved Delphi process among healthcare 
practitioners’ with expertise in medication safety and quality management. The last 
phase was a retrospective study involving review of medical charts and medication 
orders of patients’ admitted to surgical, medical and intensive care unit (ICU) of a 
private hospital in Riyadh, Saudi Arabia during four month. The  severity of the 
identified errors was assessed by two consultants using the National Coordinating 
Council for Medication Error Reporting and Prevention (NCC MERP) algorithm. 
Phase one study revealed three main themes;  medication safety problems, challenges 
to improve medication safety practices, and suggestions for improvement of 
medication safety. In phase two study a total of 35 experts accepted to participate in 
the study, of whom 31 (88.5%) responded in the first round. In the second round only 
xviii 
 
24 (68.5%) of them responded. Consensus was reached to accept the definition of 
prescribing errors. Regarding the types of prescribing errors, consensus was reached 
to include 34 scenarios, to exclude 5 scenarios and to include 3 scenarios depending 
on the individual clinical situation. In phase three study a total of 691 prescribing 
errors were identified in 2,033 patients’ files. The incidence of prescribing errors was 
3.6 (95% CI, 3.3 - 3.9) per 100 prescriptions, 33.9 (95% CI, 31.5 - 36.6) per 100 
admissions and 76.5 (95% CI, 70.9 - 82.3) per 1000 patients days. The most 
commonly identified prescribing errors type was dosing errors (127; 18.4%) with 74 
overdoses and 53 under doses. Antibiotic (230; 33.3%) was the most common drug 
class involved with prescribing errors. Out of the identified prescribing errors 20 
(2.9%) were judged to be actual, 330(47.8%) potential and 341(49.3%) prescribing 
errors with no harm. There are several challenges to medication safety in Saudi 
Arabia and prescribing errors is very common. Key recommendations to improve 
medication safety included, use of technology, continuous education competency 
assessment, rigorous research and support from national hospital accreditation 
bodies.  
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CHAPTER 1: GENERAL INTRODUCTION 
2 
 
1.1 Background 
In the last few decades, patient safety has become a global issue and has therefore 
been a focus of attention for both healthcare professionals and researchers (Kohn , 
Corrigan, & Donaldson, 1999). Despite healthcare practitioners’ efforts to provide 
safe and effective care, several studies have identified harms resulting from 
unintended medication errors. These vary in severity from minor to major, or even 
the death of the patient (Aljadhey, Mahmoud, Mayet, Alshaikh, Ahmed et al., 2013b; 
Bates, Cullen, Laird, Petersen, Small et al., 1995; Classen, Pestotnik, Evans, Lloyd 
JF, & JP., 1997). The Institute of Medicine (IOM) has reported that at least 1.5 
million Americans are injured by medication errors every year (Institute of Medicine, 
2006). Medication errors also impose an economic burden on both patients and 
healthcare providers. The cost of medication errors in the United States (US) was 
estimated at 20 billion dollars (IMS Institute for Healthcare Informatics, 2013). The 
overall cost of adverse drug events (ADEs) in the US was reported as approximately 
5.6 million dollars per year, and the cost of preventable ADEs resulting from 
medication errors was reported at 2.8 million dollars per year (Bates, Spell, Cullen, 
Burdick, Laird et al., 1997). Using these figures, it was estimated that the direct cost 
of ADEs to acute care hospitals in the US was 4 billion dollars and the cost of 
preventable ADEs due to medication errors was 2 billion dollars per year. The cost of 
preventable ADEs in community hospitals in the US was 3,511 dollars (Hug, 
Keohane, Seger, Yoon, & Bates, 2012). Preventable ADEs are also associated with 
increased length of hospital stay (Classen et al., 1997; Hug et al., 2012).  
 
Medication errors can occur at any stage of the medication use process (prescribing, 
dispensing, transcribing, administering and monitoring). A growing body of 
3 
 
literature, however, reports that medication errors, especially those causing 
preventable ADEs, most commonly occur in the prescribing stage (Aljadhey et al., 
2013b; Bates et al., 1995; Morimoto, Sakuma, Matsui, Kuramoto, Toshiro et al., 
2011). According to a recent systematic review of 65 studies published from 1985-
2007, mostly from the US or the Unite Kingdom (UK), prescribing errors occur in 
7% of medication orders, 2% of patient days and 5% of hospital admissions (Lewis, 
Dornan, Taylor, Tully, Wass et al., 2009).  
 
There is a lack of studies about medication safety issues in the Middle East 
(Alsulami, Conroy, & Choonara, 2013). Although Saudi Arabia is the third most 
common country in the Middle East to investigate medication errors (Alsulami et al., 
2013), exploratory studies enquiring about the current situation of medication safety 
in Saudi hospitals is lacking. Particularly little is known about the incidence of 
prescribing errors in hospitalised patients in Saudi Arabia. Therefore, this study aims 
to explore the challenges to medication safety from the perspective of healthcare 
professionals in Saudi Arabia and assess the incidence of prescribing errors in 
hospitalised patients using a validated definition.  
 
1.2 Study justifications 
Medication safety in Saudi hospitals has not been explored extensively. Some 
attempts have been made to explore healthcare professionals’ experiences about 
medication errors and medication errors reporting (Tobaiqy & Stewart, 2013). Few 
studies were also conducted to investigate the implementation of certain standards 
and good practice, such as creating a culture of safety (Alahmadi, 2010), basic 
medication safety practices (Aljadhey, Alhusan, Alburikan, Adam, Murray et al., 
4 
 
2013a), the use of prohibited abbreviations (Alshaikh, Mayet, Adam, Ahmed, & 
Aljadhey, 2013a) and incidents reporting at hospital level (Arabi, Alamry, Al Owais, 
Al-Dorzi, Noushad et al., 2012). As far as can be established, however, no qualitative 
studies have been made to explore healthcare professionals’ views on the subject. 
Exploratory studies are therefore needed to gain insights into the current practice of 
medication safety from the perspective of healthcare professionals. This will help 
healthcare authorities to design interventions to improve medication safety. 
 
Previous studies of prescribing errors in Saudi Arabia have used different definitions, 
and to date there have been no attempts to develop an agreed definition. This 
variability in definitions used makes it necessary to develop a validated definition to 
assess the prevalence and incidence of prescribing errors in Saudi Arabia. Predefined 
scenarios and a definition of what is and is not a prescribing error serve as a guide for 
researchers who wish to investigate this area (B. Dean, Barber, & Schachter, 2000). 
The definition also affects the number and types of errors discovered and allow 
comparisons between studies using the same definition. A definition and scenarios 
developed by Dean and colleagues in the United Kingdom (UK) have been widely 
used in other studies (Lewis et al., 2009). It is not clear, however, whether the 
definition is valid used in a different country, such as Saudi Arabia, because the 
healthcare system, and education and training of individual healthcare professionals 
may be very different.  
 
Numerous international studies have been conducted to establish the incidence of 
prescribing errors in hospitalised patients (Lewis et al., 2009). However, compared to 
western countries, few studies were conducted in the Middle East (Alsulami et al., 
5 
 
2013). In Saudi Arabia, the majority of the studies that investigated prescribing 
errors were conducted in the primary care settings (Alsulami et al., 2013; Khoja, 
Neyaz, Qureshi, Magzoub, Haycox et al., 2011; Neyaz Y, Qureshi NA, Khoja T, 
Magzoub MA, Haycox A et al., 2011) with few to date in hospital settings (Al-
Dhawailie, 2011; Al-Jeraisy, Alanazi, & Abolfotouh, 2011; Dibbi, Alabrashy, 
Hussain, Fatani, & Karima, 2006). These studies have not used a standard definition 
of prescribing errors. A study using a valid definition of prescribing errors is needed 
to estimate the incidence of prescribing errors.  
 
1.3 General study objectives  
 To explore healthcare professionals perspectives about the challenges to 
medication safety practice in Saudi Arabian hospitals.  
 To develop a consensus on the definition of prescribing errors to be used in 
the assessment of prescribing errors among hospitalised patients in Saudi 
Arabia. 
 To assess the incidence and severity of prescribing errors. 
 
1.4 Thesis overview 
This thesis consists of seven chapters, covering introduction, method, results and 
discussion. Chapter two, the literature review, discusses medication safety. It also 
contains a detailed and up-to-date discussion of published studies on incidence, 
prevalence, severity, and causes of, and risk factors associated with, prescribing 
errors. Chapter three discusses the methodology, and in particular, possible 
methodological approaches to achieve the objectives. Chapter four describes the 
qualitative part of the study. It includes an in-depth analysis of a round-table 
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discussion about medication safety challenges with healthcare professionals in Saudi 
Arabia. Chapter five includes the result of a Delphi study involving practitioners with 
a special interest in medication safety and quality of healthcare. It validates the 
definition of prescribing errors and the scenarios for use in Saudi Arabia. Chapter six 
is the quantitative part of the study and includes the epidemiology of prescribing 
errors. It provides data on incidence, types, severity, medication involved and factors 
associated with prescribing errors. Chapter seven provides an overall conclusion, 
recommendations and limitations from the thesis findings.  
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CHAPTER 2: LITERATURE REVIEW 
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2.1 The healthcare system in Saudi Arabia 
Saudi Arabia is located in southwest Asia and covers an area of 2.250 million square 
kilometres (The Saudi Ministry of External Affairs, 2013) with a population of 
30,770,375 in 2014 (Central Department of Statistics & Information, 2014). Saudi 
citizens make up 67.9% of the total population; 50.2% are male and 49.8% are 
female. Saudi Arabia is among the richest countries in the Middle East. According to 
the 2014 Human Development Report from the United Nations, Saudi Arabia was 
ranked 34 out of 187 countries, with a Human Development Index of 0.83, which is 
considered very high (Human Development Report, 2014). It is generally agreed to 
be the world’s largest oil producer and exporter and possesses one-fifth of the 
world’s oil reserves (U.S. Energy Information Administration, 2013).  
 
The government expenditure on the Ministry of Health (MOH) has increased from 
6.2% of the total government budget in 2009 (Central Department of Statistics & 
Information, 2009) to 6.6% in 2013 (Ministry of Health, 2013). The total number of 
hospitals in the country increased from 408 in 2009 to 445 in 2013 and the number of 
beds increased from 55,932 in 2009 to 64,777 in 2013 (Ministry of Health, 2013). 
The main government organisations that provide healthcare services are the MOH 
hospitals, primary healthcare centres, other government hospitals and private 
hospitals. The MOH is the major provider of healthcare services and has 268 
hospitals with 38,970 beds, followed by the private sector with 136 (30.6%) hospitals 
and 14,310 beds. Other government hospitals include 39 (9.6%) hospitals with 
10,822 (19.3%) beds (Ministry of Health, 2013). In total, 39 (9.6%) hospitals and 
11,497 beds are provided by other government organisation, including the National 
Guard, Armed Forces, security forces, teaching hospitals and Health Services in the 
9 
 
Royal Commission for Jubail and Yanbu (Ministry of Health, 2013). The majority of 
these hospitals deliver services to employees and their dependents. All services in 
government hospitals are provided free of charge; private hospitals charge for 
services.  
 
Private hospitals are the second main provider of healthcare in Saudi Arabia 
(Ministry of Health, 2013). The number of private hospitals increased from 125 
hospitals in 2009 to 136 in 2013 (Ministry of Health, 2013). In 2013 the highest 
percentage of private hospitals was present in Jeddah (24.2%) followed by Riyadh 
(23.5%) (Ministry of Health, 2013). However, the highest number of hospital beds 
were present in Riyadh (30.5% of the total number of hospital beds) followed by 
Jeddah (21.2% of the total number of hospital beds).   
 
The quality of healthcare institutions in Saudi Arabia is monitored by the Saudi 
Central Board for Accreditation of Healthcare Institutions (CBAHI), the official 
body authorised to award quality accreditation to healthcare institutions in Saudi 
Arabia. As part of their initiatives to deliver safe care and keep up-to-date with 
international standards, some Saudi hospitals, including government non-MOH and 
some big private hospitals have sought accreditation from national and international 
bodies. Some of the top hospitals in the country have sought Canadian accreditation, 
which provides an external healthcare quality peer review process for national and 
international hospitals.  
 
The safety of drugs, food and medical and diagnostic devices in Saudi Arabia are 
monitored by the Saudi Food and Drug Authority (SFDA), established in 2003 
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(Saudi Food & Drug Authority, 2013). It covers three main sectors, food, drugs and 
medical devices. It is also responsible for developing clear policy and procedures for 
the use of drugs and monitoring the implementation of these policies. 
 
In March 2009, the SFDA launched the Saudi Pharmacovigilance Centre and joined 
the World Health Organization (WHO) International Drug Monitoring Program 
(Olsson, 2009). The Saudi Pharmacovigilance Centre created the Saudi Adverse 
Events Reporting System (SAERS) to receive reports from healthcare professionals, 
the pharmaceutical industry and the general public on adverse drug reactions 
(ADRs), quality problems, unexpected lack of efficacy and drug poisoning. 
(Alshammari, Al-Kathiri, Le Louet, & Aljadhey, 2015).  
 
2.2 Defining medication errors 
According to a recent systematic review covering definition and characteristics of 
medication errors, there are at least 26 different generic definitions of medication 
errors (Lisby, Nielsen, Brock, & Mainz, 2010). Perhaps the most comprehensive 
definition is that given by the National Coordinating Council for Medication Errors 
Reporting and Prevention (NCC MERP), which defined medication errors as "Any 
preventable event that may cause or lead to inappropriate medication use or patient 
harm while the medication is in the control of the health care professional, patient, or 
consumer. Such events may be related to professional practice, health care products, 
procedures, and systems, including prescribing, order communication, product 
labeling, packaging, and nomenclature, compounding, dispensing, distribution, 
administration, education, monitoring, and use.”(National Coordinating Council for 
Medication Error Reporting and Prevention (NCCMERP), 2014).  
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More narrowly the National Patient Safety Agency (NPSA) defined Medication 
errors as any errors in the medication use processes (prescribing, dispensing, 
administering, transcribing and monitoring) (National Patient Safety Agency, 2007).  
 
2.3 Defining medication errors in the prescribing stage  
Medication errors that occur during prescribing stage is called prescribing errors. 
Any definition of prescribing errors should consider the main elements of the 
prescribing process; for example the choice of medicine should be appropriate to the 
patient and the condition (Aronson J.K, 2004). The prescribing process should 
minimise harm and consider the balance between harm and benefit (Aronson J. K, 
2006). Several definitions of prescribing errors have been reported in the literature 
(Lewis et al., 2009). Prescribing/ordering of drugs includes a decision making 
component and a technical component. Errors can occur in both parts of this process. 
For example, one definition is an error in the process of prescribing medication that 
leads to or has the potential to lead to patient harm (Aronson J. K, 2009). Dean and 
colleagues (2000) used a two-stage Delphi method with healthcare professionals 
(physician, pharmacists and nurses) having a special interest in medication errors and 
risk management, to develop an operational definition, concluding that “A clinically 
meaningful prescribing error occurs when, as a result of a prescribing decision or 
prescription writing process, there is an unintentional significant (1) reduction in the 
probability of treatment being timely and effective or (2) increase in the risk of harm 
when compared with generally accepted practice”. In this definition the word 
“unintentional” was used to exclude the risk of harm from malicious acts (Avery, 
Barber, Ghaleb, Dean, Armstrong et al., 2012). The statement “compared with 
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generally accepted practice” was included because the preventability of the 
prescribing error depends on the generally accepted practice. The word “significant” 
was used to include only clinically meaningful prescribing errors and cognitive errors 
with adverse consequences, and to ensure that the findings would be relevant and 
worthy ( Avery et al., 2012). This definition was accompanied by 27 scenarios that 
should be included as prescribing errors, eight that should be excluded and seven 
where judgment depends on the individual clinical situation (Appendix A). These 
scenarios provide some clarity on potentially controversial cases to help decide on 
the inclusion and exclusion of prescribing errors. This definition is widely accepted 
(Lewis et al., 2009) and has been used in several studies (Avery, Ghaleb, Barber, 
Dean, Armstrong et al., 2013; Dean, Reynolds, Shebl, Burnett, & Jacklin, 2011; 
Keers, Williams, Vattakatuchery, Brown, Miller et al., 2014; Ryan, Ross, Davey, 
Duncan, Francis et al., 2014; Seden, Kirkham, Kennedy, Lloyd, James et al., 2013).  
 
Other definition of prescribing errors was given by the American Society of Hospital 
Pharmacist (ASHP). The ASHP defined prescribing errors as “incorrect drug 
selection (based on indications, contraindications, known allergies, existing drug 
therapy, and other factors), dose, dosage form, quantity, route, concentration, rate of 
administration, or instructions for use of a drug product ordered or authorised by 
physician (or other legitimate prescriber); illegible prescriptions or medication orders 
that lead to errors that reach the patient” (American Society of Hospital Pharmacists, 
1993). Agalu et al. (2011) defined prescribing errors as deviation from standard 
practices (as indicated in national standard treatment guidelines, textbooks, 
handbooks, and software) excluding dosage form errors, illegible hand writing, and 
failure to authenticate the prescription with signature and/or date. Dale et al. (2003) 
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defined prescribing errors as an error which caused an adverse drug event (ADE) 
(ADE; an injury resulting from medical intervention related to a drug) or was judged 
to represent a potential ADE (an error that has the capacity to cause injury but fails to 
do so either by chance or because it is intercepted). The Pharmaceutical Care 
Network Europe (Pharmaceutical Care Network Europe , 2010) classification of drug 
related problems was also used by few studies (Glanzmann et al., 2015). This 
classification consists of  drug selection (the cause of the MPE can be related to the 
selection of the drug, i.e. no indication for drug, inappropriate combination of drugs 
(interactions), indication for drug treatment not noticed and too many drugs 
prescribed for indication), drug formulation (the cause of the MPE is related to the 
selection of the drug formulation), dose selection (the cause of the MPE can be 
related to the selection of the dosage schedule), treatment duration (the cause of the 
MPE is related to the duration of therapy), drug use process (the cause of the MPE 
can be related on the way the patient gets the drug administered), or other problems 
(Pharmaceutical Care Network Europe , 2010).  
 
Studies investigating prescribing errors in Saudi Arabia have not used a standard 
definition of prescribing errors. For example Al-Dhawailie (2011) categorised 
prescribing errors as “wrong patient, wrong drug, wrong dose, wrong strength, wrong 
frequency, wrong drug combination, and unclear written medication orders or 
inpatient drug charts”. Another Saudi study defined prescribing errors as “an 
incorrect or inappropriate drug selection (based on indications, contraindications 
and other factors), dose, route, rate of administration, or frequency. A 
prescription error also included illegible handwriting, an incomplete order 
(missing the dose, route, or frequency), incompatibility, incorrect instructions for 
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using the drug product, and  the use of non-standard nomenclature or 
abbreviations that requires further interpretation.” (Al-Jeraisy et al., 2011). 
Both studies provided different definitions of prescribing errors. These differences in 
definitions led to some inconsistencies. For example, an incomplete medication order 
was considered as a prescribing error by one study (Al-Jeraisy et al., 2011) and not 
by the other study (Al-Dhawailie, 2011).  
 
In this thesis The definition of Dean et al (2000) was used because it is the most 
comprehensive definition available. It provides scenarios of prescribing errors 
(Appendix A) which are very easy to follow and help to classify the types of 
prescribing errors. In addition this definition was widely used by many studies  to 
investigate the incidence of prescribing errors worldwide (Lewis et al., 2009).  
 
2.4 Defining Adverse Drug Events 
An Adverse drug events (ADE) is defined as injury resulting from medical 
intervention related to a drug (Bates et al., 1995; National Patient Safety Agency, 
2007). ADEs can be potential or actual. Potential ADEs, also known as ‘near 
misses’, are incidents that did not cause harm but had the potential to do so (National 
Patient Safety Agency, 2007). Actual ADEs involve harm caused by medication and 
include both ADRs and medication errors (Figure 2.1). An ADR is defined by the 
WHO as “A response to a drug which is noxious and unintended, and which occurs 
at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, 
or for the modifications of physiological function” (World Health Organization, 
2002).  
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An ADE can be preventable or non-preventable. Preventable ADEs happen because 
of medication errors and result in patient harm (Bates et al., 1995; National Patient 
Safety Agency, 2007). Examples of preventable ADEs include prescribing a 
medication to a patient with a known allergy to that medication and prescribing the 
correct medication by the wrong route of administration (National Patient Safety 
Agency, 2007). Non-preventable ADEs are harms not caused by medication errors. 
An example of non-preventable ADEs includes a side effect to a medication that was 
prescribed to the patient for the first time (National Patient Safety Agency, 2007). 
The relationship between medication errors, ADEs and ADRs are illustrated in figure 
Figure 2.1: Relationship between Medication 
Errors, ADEs and ADRs (Morimoto, Gandhi, 
Seger, Hsieh, & Bates, 2004) 
 
 
 
 
 
Potential 
ADES 
ADEs 
Medication Errors 
Preventable ADEs  
Adverse Drug 
Reactions 
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2.1 (Bates et al., 1995; Morimoto et al., 2004; National Patient Safety Agency, 
2007). This thesis focuses on medication errors in the prescribing stage of medication 
use process and their severity. 
 
2.5 Incidence, prevalence, types and medications associated with prescribing 
errors in Europe, US, Canada and Australia 
 
2.5.1 Introduction 
Literature search were conducted for studies investigating the prevalence, incidence 
and types of prescribing errors in hospital inpatients. Searches were conducted for 
articles published in English language only. Studies investigating prescribing errors 
involving specific medication or medication classes and those investigating the 
incidence of one type of prescribing errors (example, dosing errors) were excluded. 
Table 2.1 shows studies investigating the incidence, prevalence, types and 
medications associated with prescribing errors in Europe, US, Canada and Australia. 
 
2.5.2 Countries 
The majority of the studies were conducted in the UK (Abdel-Qader, Harper, 
Cantrill, & Tully, 2010; Ashcroft, Lewis, Tully, Farragher, Taylor et al., 2015; 
Basey, Krska, Kennedy, & Mackridge, 2014; B. Dean, O'Grady, Paschalides, Utley, 
Gallivan et al., 2007; B.  Dean et al., 2011; Ghaleb, Barber, Franklin, & Wong, 2010; 
Keers et al., 2014; Mandal & Fraser, 2005; Ridley, Booth, & Thompson, 2004; 
Seden et al., 2013; Shulman, Singer, Goldstone, & Bellingan, 2005; Tully & Buchan, 
2009) and US (Bobb, Gleason, Husch, Feinglass, Yarnold et al., 2004; Cimino, 
Kirschbaum, Brodsky, & Shaha, 2004; Echeta, Moffett, Checchia, Benton, Klouda et 
al., 2014; Grasso, Genest, Jordan, & Bates, 2003; Hendey, Barth, & Soliz, 2005; 
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Sard, Walsh, Doros, Hannon, Moschetti et al., 2008; Taylor, Selbst, & Shah, 2005). 
Other countries included Canada  (Forster et al., 2004), France (Caruba, Colombet, 
Gillaizeau, Bruni, Korb et al., 2010), Scotland (Ryan et al., 2014), Japan (Morimoto 
et al., 2011), the Netherland (Van Den Bemt et al., 2009) and Switzerland 
(Glanzmann et al.., 2015).  
 
2.5.3 Study Design 
The study design of the reviewed studies were either prospective or retrospective. 
Prospective studies were more most common compared to retrospective studies 
(Table 2.1). Either medical chart review or prescription review or both were 
conducted in majority of the studies. Data were most commonly collected by 
pharmacists or nurses.  
 
2.5.4 Setting 
Studies were most commonly carried out in teaching hospitals (Bacic Vrca, 
Becirevic-Lacan, Bozikov, & Birus, 2005a; Bobb et al., 2004; Caruba et al., 2010; 
Colpaert, Claus, Somers, Vandewoude, Robays et al., 2006; B. Dean et al., 2007; B.  
Dean et al., 2011; Forster, Halil, & Tierney, 2004; Lisby, Nielsen, & Mainz, 2005; 
Ridley et al., 2004; Shulman et al., 2005; P. M. L. A. Van Den Bemt, Zaal, Egberts, 
Lenderink, Kosterink et al., 2009). Few studies were conducted in specialized 
hospitals (Glanzman et al., 2015; Ghaleb et al., 2010; Mandal & Fraser 2005; Grasso 
et al., 2003). One study was a multinational study conducted in Newzealand and 
Australia (Barton, Futtermenger, Gaddi, Kang, Rivers et al. 2012). Few studies were 
also conducted in multiple hospitals (Seden et al., 2013; Dean et al., 2011; Ryan et 
al., 2014; Marimoto et al., 2011; Cimino et al., 2004; Ghaleb et al., 2010).  
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2.5.5 Incidence of prescribing errors 
The incidence of prescribing errors in Europe, US, Canada and Australia ranged 
from (0.9% to 94%). The rate of prescribing errors was reported per number of 
admissions, patient-days and number of medication orders. The lowest incidence 
(0.9%) was reported by a prospective study conducted in seven medical wards of a 
teaching hospital in France (Caruba et al., 2010). The highest incidence (94%) was 
reported by a prospective study conducted in three sites in Australia and one in New 
Zealand (Barton et al., 2012).  
 
2.5.6 Type of prescribing errors 
Omission of the required drug therapy including omission of medications on 
admission, on rewriting of prescriptions and on discharge (Ashcroft et al., 2015; 
Seden et al., 2013; Taylor et al., 2005; Keers et al. 2014; Dean et al., 2011; Ryan et 
al., 2014; Basey et al., 2014) and dosing errors (overdosing, undersosing and dose 
selection) (Ashcroft et al., 2015; Bobb et al. 2004; Seden et al., 2013; Colpaert et al., 
2006; Glanzmann, Frey, Meier, & Vonbach, 2015; Hendey et al., 2005; Basey et al., 
2014) were the most frequently reported types of prescribing errors. Other 
prescribing errors included incomplete prescription such as missing the 
dose/frequency of medication and wrong frequency of medications  administration 
were common types of prescribing errors.  Prescribing errors such as wrong infusion 
rates and use of abbreviation were the least commonly identified errors (Table 2.1). 
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2.5.7 Medications associated with prescribing errors 
The most common medication class associated with prescribing errors was 
antibiotics (Bobb et al., 2004; Colpaert et al., 2006), but some studies did not report 
the medication class. 
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Table 2.1 Incidence, prevalence, types and medications associated with prescribing errors in Europe, US, Canada and Australia 
Setting Study design Duration 
of the 
Study  
Population Sample Rate of 
prescribing 
errors 
reported 
Types of 
prescribing 
errors 
Medication 
classes involved 
Reference 
UK (20 
National 
health 
service 
hospitals) 
Prospective 
study 
Seven days Patients 
admitted to 
the 20 
hospitals 
during the 
study period. 
26,019 
patients and 
124,260 
medication 
orders 
8.8% (10,986 
of the 
124,260 
medication 
orders) 
Omission 
(28.5%), under-
dosage (10.9 
%), over-dosage 
(8.4 %), 
strength/dose 
missing (7.6%) 
and 
administration 
times incorrect/ 
Missing (6.6%) 
Cardiovascular, 
central nervous 
system, 
respiratory, 
endocrine, and 
gastrointestinal 
drugs (73.1 %)  
Ashcroft et 
al. (2015) 
US 
(Teaching 
hospital) 
Prospective 
study 
One week Inpatients 
and 
emergency 
department 
admissions 
17808 
medication 
orders.  
6.2% (1111 
errors of the 
17808 
medication 
orders) 
Of 342 
clinically 
significant 
errors, 39 % 
were dosing 
errors, 20 % 
wrong 
frequency and 
9.4% 
nomenclature 
errors 
Anti-infectives 
(37%), 
cardiovascular 
drugs (12.3%), 
opoid analgesics 
(7.6%) and 
vitamins/ 
Electrolytes 
(3.8%) 
Bobb et al. 
(2004) 
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Table 2.1 Incidence, prevalence, types and medications associated with prescribing errors in Europe, US, Canada and Australia  
Setting Study 
design 
Duration of 
the Study  
Population Sample Rate of 
prescribing 
errors 
reported 
Types of 
prescribing 
errors 
Medication 
classes involved 
Reference 
Canada 
(Teaching 
hospital) 
Prospective 
study 
One month General 
medical 
ward 
543 patient-
days 
23.9 per 1000 
patient-days 
(13error 
occurred during 
the  543 
patient-days ) 
NR Reported for all 
ADEs 
Forster et 
al. (2004) 
France (7 
medical 
wards of a 
teaching 
hospital) 
Prospective 
study 
18 days Seven 
medical 
wards 
204 
patients 
with 12 533 
medication 
orders  
0.9% (117 
errors  of the 12 
533 medication 
orders) 
Inappropriate 
choice of drugs 
(56.4%), 
omission 
(20.5%) and 
drug-drug 
interaction 
(13.7%) 
NR Caruba et 
al. (2010) 
NR= Not Reported 
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Table 2.1 Incidence, prevalence, types and medications associated with prescribing errors in Europe, US, Canada and Australia 
Setting Study 
design 
Duration of 
the Study  
Population Sample Rate of 
prescribing 
errors reported 
Types of 
prescribing 
errors 
Medication 
classes 
involved 
Reference 
North West 
UK (teaching 
hospitals, 
district 
hospitals and 
specialist 
hospitals s for 
paediatrics, 
women and 
mental 
health) 
Prospective 
study 
Three weeks Nine 
hospitals 
4238 
prescriptions
71% (3011 errors 
in the 4238 
prescriptions)  
 
Omission  
(26.9%), 
writing errors 
(20.7%), 
dosing errors 
(20.6%) 
NR Seden et al. 
(2013)  
North West 
UK (National 
Health 
Service 
(NHS) mental 
health 
hospitals in 
the North 
West of 
England.) 
Prospective 
study 
10 days Three mental 
health 
hospitals 
4427 
prescriptions
6.3% (281 of the 
4227 
prescriptions) 
Omission 
(12.5%), 
incorrect or 
missing 
admission 
times/frequency 
(11.7%) and 
missing 
strength or 
doses (10.4%)  
NR Keers et al. 
(2014) 
NR= Not Reported 
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Table 2.1 Incidence, prevalence, types and medications associated with prescribing errors in Europe, US, Canada and Australia 
Setting Study 
design 
Duration of 
the Study  
Population Sample Rate of 
prescribing 
errors 
reported 
Types of 
prescribing 
errors 
Medication 
classes 
involved 
Reference 
UK (two 
teaching and 
one non-
teaching 
hospital) 
Prospective 
study 
Two weeks 
in each ward 
Patients 
admitted to 
medical and 
surgical wards
6605 
medication 
orders and 
1771 patient 
days. 
15.5% (1025 
prescribing 
errors were 
identified 
in the 6605 
medication 
orders) 58% 
(1025 
prescribing 
errors were 
identified 
during  the 
1771 patient 
days) 
Omission, 
inappropriate 
dose, 
Incomplete 
prescription. 
NR Dean et al. 
(2011) 
Scotland 
 (eight 
hospitals ) 
Prospective 
study 
28 weeks Adult 
medical, 
surgical, 
acute and 
long stay 
patients 
4710 patient 
charts and 
44,726 
prescribed 
medicines 
36%  (1700 of 
the 4710 
prescription 
charts )  
Omission 
(28.6%), 
incomplete 
prescription 
(15.7%), sub 
therapeutic 
dose (7.8%) 
and incorrect 
dose (7.1%) 
NR Ryan et al. 
(2014) 
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Table 2.1 Incidence, prevalence, types and medications associated with prescribing errors in Europe, US, Canada and Australia 
Setting Study design Duration of 
the Study  
Population Sample Rate of 
prescribing 
errors 
reported 
Types of 
prescribing 
errors 
Medication 
classes 
involved 
Reference 
Belgium 
(ICU of a 
teaching 
hospital) 
Prospective 
study 
Five weeks ICU 1224 
prescriptions 
and 80 
patient-days. 
27% (331 
errors of the 
1224 
prescriptions)  
Dosing error 
(48%), wrong 
infusion rate 
(18%), wrong 
frequency 
(9%).   
Antibiotics 
(23.5%), 
cardiovascular 
medications 
(23%), 
sedatives 
(19.8%) 
Colpaert et 
al. (2006) 
Denmark 
(Teaching 
hospital) 
Prospective 
study 
Four 
months 
Patients 
admitted to 
medical and 
surgical ward 
433 
medication 
orders 
38.6% (167 of 
the 433 
medication 
orders) 
Drug 
formulation 
(37.9%), 
omission of 
route (34.7%) 
and wrong 
treatment 
time (10%) 
NR Lisby et al. 
(2005) 
NR= Not Reported 
 
 
 
 
 
